These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 12437489)

  • 1. Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?
    Doggrell SA
    Expert Opin Pharmacother; 2002 Nov; 3(11):1543-56. PubMed ID: 12437489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor blockers in older patients.
    Weber MA
    Am J Geriatr Cardiol; 2004; 13(4):197-205; quiz 206-7. PubMed ID: 15269566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of angiotensin II inhibition in cardiovascular medicine.
    Meier P; Maillard M; Burnier M
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Feb; 5(1):15-30. PubMed ID: 15720221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism.
    Brunner-La Rocca HP; Vaddadi G; Esler MD
    J Am Coll Cardiol; 1999 Apr; 33(5):1163-73. PubMed ID: 10193712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blockers: evidence for preserving target organs.
    Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
    Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE inhibitors in heart failure: prospects and limitations.
    Pitt B
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():285-90. PubMed ID: 9211022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
    Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
    J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor antagonists and ACE inhibitors.
    Howes LG; Christie N
    Aust Fam Physician; 1998 Oct; 27(10):914-7, 919-21. PubMed ID: 9798290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
    Rodgers JE; Patterson JH
    Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG; White WB
    Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?
    Taylor AA
    Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):643-8. PubMed ID: 11496059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
    Weir MR; Henrich WL
    Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.
    Parmley WW
    Am J Med; 1998 Jul; 105(1A):27S-31S. PubMed ID: 9707265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.